<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00067301</url>
  </required_header>
  <id_info>
    <org_study_id>R21AT001077</org_study_id>
    <secondary_id>GertsikL</secondary_id>
    <nct_id>NCT00067301</nct_id>
  </id_info>
  <brief_title>PUFA Augmentation in Treatment of Major Depression</brief_title>
  <official_title>PUFA Augmentation in Treatment of Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Center for Complementary and Integrative Health (NCCIH)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed up
      response to antidepressant therapy with Celexa (Citalopram) in people suffering from Major
      Depressive Disorder. All patients will receive Celexa, 50% will receive EPA, 50% placebo EPA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As per brief summary
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>Major Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyunsaturated Fatty Acids (PUFA)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet DSM-IV criteria for current major depression, and have a HAM-D (21 item) score of
             &gt; 17

          -  Male or female who, if of child-bearing potential, agrees to use effective
             contraception including the regular use of contraceptive pills, intra-uterine devices,
             barrier methods or abstinence

          -  Age between 18 and 65

          -  Capable of giving informed consent

        Exclusion Criteria:

          -  Diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder,
             schizotypal disorder, psychotic depression or bipolar disorders

          -  Current drug or alcohol abuse or dependence, or history of drug or alcohol abuse or
             dependence within the previous 6 months

          -  Unstable medical or neurological conditions that are likely to interfere with the
             treatment of depression

          -  History of allergy to citalopram or ProEPA, finfish or shellfish

          -  History of failure of response to citalopram, as documented by an adequate trial of
             the medication [defined as having been treated with the medication at a dose level
             typically regarded as adequate (i.e., 40 mg of citalopram per day) for at least 6
             weeks]

          -  History of seizure disorder

          -  Pregnancy

          -  Currently on psychotropic medications including antidepressants or neuroleptics

          -  Active suicidal ideation or other safety issues determined by the clinician to not be
             suitable for inclusion in the study

          -  Exposure to treatment with fluoxetine or MAOIs in the previous two months

          -  Patients on anticoagulant therapy

          -  Patients with a dietary intake of &gt; 3.0g total omega-3 PUFA/day at baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lev Gertsik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center Dept. of Psychiatry</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2003</study_first_submitted>
  <study_first_submitted_qc>August 14, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2003</study_first_posted>
  <last_update_submitted>January 23, 2008</last_update_submitted>
  <last_update_submitted_qc>January 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2008</last_update_posted>
  <keyword>depression</keyword>
  <keyword>citalopram</keyword>
  <keyword>Celexa</keyword>
  <keyword>Polyunsaturated Fatty Acids</keyword>
  <keyword>omega-3</keyword>
  <keyword>EPA</keyword>
  <keyword>antidepressants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

